Chicago, IL (PRWEB) May 30, 2012
MEDIA INVITATION: Learn about a groundbreaking treatment for cancer straight from the experts!
Join leading cancer researchers and learn about immunotherapy as a treatment option in the fight against cancer at the SITC Primer on Tumor Immunology and Cancer Immunotherapy™ From Biology to Treatment on Friday, June 1, from 8:00 a.m. - 1:00 p.m. leading into the 2012 ASCO Annual Meeting.
Members of the media can register free of charge for a press pass and will have access to:
- Insight into how immunotherapy translates to the clinic and impacts patient care
- Updates on the recent FDA approvals of two new immunotherapeutic strategies
- Information on the fundamental mechanisms of action of these new agents
- The latest advances in tumor antigens and vaccination, checkpoint blockade,
co-stimulation and adoptive immunotherapy
- One-on-one access to leaders in the field of cancer immunotherapy research
This is a pivotal time for the field of cancer immunotherapy given the recent FDA approvals of two new immunotherapeutic strategies and evidence for clinical activity with several additional approaches being tested clinically. Increased excitement and success with immunotherapy has been driven by a deeper understanding of the mechanisms by which the immune system can destroy cancer, as well as the resistance mechanisms employed by the tumor that need to be overcome. The long durability of clinical benefit with immune-based therapies is an attractive feature that is not usually seen with most other cancer treatments. As such, immunotherapy is now being viewed as a valuable treatment option and a welcome addition to the armamentarium of cancer therapeutics.
Founded in 1984, the Society for Immunotherapy of Cancer (formerly the International Society for Biological Therapy of Cancer; iSBTc) is a non-profit organization of clinicians, researchers, students, post-doctoral fellows, and allied health professionals dedicated to improving cancer patient outcomes by advancing the development and application of cancer immunotherapy through interaction, innovation and leadership. For more information about SITC, please visit the Society website at http://www.sitcancer.org.
Contact: Jennifer Warren
Ph: (414) 271-2456